Edison Investment Research - Suda (SUD) Suda Pharmaceuticals - A potentially transformational acquisition

Report

Edison Investment Research

Sean Conroy

Suda Pharmaceuticals - A potentially transformational acquisition

SUDA recently announced that it will be licensing an invariant natural killer T (iNKT) cell therapy platform from Imperial College London that can be used in conjunction with chimeric antigen receptors (CARs) to target blood cancers. Specific financial terms are undisclosed but include an upfront fee, annual maintenance fees, milestones and a single-digit royalty. There are a number of potential benefits of CAR-iNKT, including the prospect of being an allogeneic ‘off-the-shelf’ therapy, significantly simplifying the manufacture of the therapy and its delivery to patients. The therapy is expected to enter the clinic in 12–24 months.

23/06/2021 6 EN

Underlying

Suda

Suda Pharmaceuticals is engaged in the pharmaceutical development of drug delivery technology; and medical devices and consumables distribution. The drug delivery operation includes the ArTiMist™ project and the oro-mucosal spray drug delivery technology. Co.'s segments include: Suda, which is the pharmaceutical development segment and performs research and development to create new human pharmaceutical products by combining proven drugs with delivery technologies; Westcoast Surgical and Medical Supplies, which is the sales and logistics operation for medical devices and consumables; and Malaria Research Company, which is the pharmaceutical development segment for the treatment of malaria.

See profile

AU000000SUD7 Australian Securities Exchange Australia

Provider

Edison Investment Research

Edison is an investment research and advisory company, with offices in North America, Europe, the Middle East and AsiaPac. The heart of Edison is our world renowned equity research platform and deep multi-sector expertise. At Edison Investment Research, our research is widely read by international investors, advisors and stakeholders. Edison Advisors leverages our core research platform to provide differentiated services including investor relations and strategic consulting.

See profile

Analysts

Sean Conroy

Other Reports on these Companies

Edison Investment Research

Suda Pharmaceuticals - Half-year update

SUDA continues to make progress with anagrelide. In an animal model, SUDA was able to show that an oral spray formulation had 43% higher bioavailability over a capsule form while only showing a 28% increase in exposure of the cardiostimulatory metabolite. This provides evidence that this formulation may allow for a lower dose of anagrelide, maintaining efficacy, but with reduced cardiotoxicity, a significant issue with the capsule formulation. In February, the company announced that it has contracted with MedPharm to perform additional formulation work to stabilise and optimise the oral spray ...

March 11, 2021 March 11, 2021 1 EN

Edison Investment Research

Suda Pharmaceuticals - A TGA approval and a capital raise

SUDA has had a busy couple of months, announcing approval for ZolpiMist in Australia by the Therapeutics Goods Administration (TGA) in July, as well as raising A$4.1m in additional capital. The TGA approval demonstrates SUDAâ€™s compliance with Good Manufacturing Practice (GMP) as well as an ability to obtain regulatory approvals. This approval will assist SUDAâ€™s current partners in their submissions in the territories for which they are responsible.

September 3, 2020 September 3, 2020 5 EN

Diverse Income Trust (The) - Could be the time for UK equities to shine

The Diverse Income Trust (DIVI) is a member of the 18-strong AIC UK Equity Income sector. It has a differentiated multi-cap income strategy and therefore its performance can differ meaningfully from those of its peers. Managers Gervais Williams and Martin Turner at Premier Miton Investors are very bullish on the outlook for UK stocks, which they believe can outperform overseas mainstream equity indices due to very attractive valuations and income prospects. They note that with global profit margins at all-time highs and increased geopolitical tensions, there could be a change in investor behav...

21h / 52m 21h / 52m 1 EN

Richard Williamson

Richard Williamson

Altron - Strong earnings growth in H125

Altron has provided an H125 trading update pointing to a more than doubling of headline EPS from continuing operations and an even larger increase in reported EPS. Having restated comparatives to reflect the move of Altron Document Solutions back to continuing operations, the improving performance of the remaining discontinued operation has become clearer, showing significantly reduced losses year-on-year. We maintain our forecasts pending the H125 results on 4 November.

22h / 19m 22h / 19m 1 EN

Pedro Fonseca

Pedro Fonseca

JPMorgan European Discovery Trust - European small caps: On the verge of a rebound?

JPMorgan European Discovery Trust (JEDT) invests in European small-cap companies (excluding UK). European small caps have outperformed most other markets over the long term, although they underperformed large caps in 2022 and 2023, as the sector was confronted with a number of challenges. Against this unfavourable backdrop, JEDT underperformed as a result of asset allocation decisions. Following a strategic review, JEDT’s board appointed three new managers, Jon Ingram, Jack Featherby and Jules Bloch, who replaced Francesco Conte and Edward Greaves with effect from 1 March 2024. The trust’s rel...

22h / 51m 22h / 51m 1 EN

Sign-up for free to access full reports immediately

Email Address*

Choose Password* ( 6 or more characters )

Due to regulatory restrictions regarding the distribution of financial research, this report is restricted to a specific region or investor type. Get access to exclusive reports by answering the questions below.

Select your country*

Get financial insights straight to your inbox

By clicking "register" you accept the Terms and Conditions & Privacy Policy

Already on ResearchPool?

Almost there...

Are you a professional investor?

Select your country

REGISTER

Create a free ResearchPool account to access full reports, get a personalised dashboard and follow providers or companies

In order to access this report please create an account.

LOGIN

Suda Pharmaceuticals - A potentially transformational acquisition

Suda Pharmaceuticals - Half-year update

Suda Pharmaceuticals - A TGA approval and a capital raise

Diverse Income Trust (The) - Could be the time for UK equities to shine

Altron - Strong earnings growth in H125

JPMorgan European Discovery Trust - European small caps: On the verge of a rebound?

Create a free ResearchPool account to access full reports, get a personalised dashboard and follow providers or companies

Sign-up for free to access full reports immediately

ResearchPool Subscriptions

Get the most out of your insights

Why subscribe?

How to subscribe

ResearchPool Subscriptions

This report is only available to subscribers

Why subscribe?

How to subscribe